EVALUATING SHORT-TERM COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE-2 DIABETES IN A CHINESE SETTING

被引：0

作者：

Fan, C. S. ^{[1
]}

Zhong, J. ^{[2
]}

Sun, F. ^{[3
]}

Liu, F. ^{[3
]}

机构：

[1] Peking Univ, Hlth Sci Ctr, Beijing 100871, Peoples R China

[2] Peking Univ, Beijing 100871, Peoples R China

[3] Novo Nordisk China Pharmaceut Co Ltd, Beijing, Peoples R China

来源：

VALUE IN HEALTH | 2013年 / 16卷 / 03期

关键词：

D O I：

10.1016/j.jval.2013.03.812

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A162 / A163

页数：2

共 50 条

[21] A SHORT-TERM COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE U100 AND INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON BASAL INSULIN
Zhou, L.
Zhou, N.
Hu, M.
[J]. VALUE IN HEALTH, 2022, 25 (07) : S386 - S386
[22] COST-EFFECTIVENESS OF EXENATIDE VERSUS INSULIN GLARGINE FOR THE TREATMENT OF TYPE-2 DIABETES IN TURKEY: A LONG-TERM HEALTH ECONOMIC ANALYSIS
Bruhn, D.
Malhan, S.
Kavuncubasi, S.
Smith-Palmer, J.
Reed, V
[J]. VALUE IN HEALTH, 2009, 12 (07) : A406 - A406
[23] Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
Hunt, Barnaby
Mocarski, Michelle
Valentine, William J.
Langer, Jakob
[J]. ADVANCES IN THERAPY, 2017, 34 (04) : 954 - 965
[24] Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
Barnaby Hunt
Michelle Mocarski
William J. Valentine
Jakob Langer
[J]. Advances in Therapy, 2017, 34 : 954 - 965
[25] SHORT-TERM COST-EFFECTIVENESS OF INSULIN DETEMIR VERSUS NPH INSULIN IN INSULIN-NAIVE SUBJECTS WITH TYPE 2 DIABETES IN SWEDEN
Ridderstrale, M.
Ericsson, A.
Jensen, M. M.
[J]. VALUE IN HEALTH, 2011, 14 (07) : A480 - A480
[26] Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
Evans, Marc
Chubb, Barrie
Gundgaard, Jens
[J]. DIABETES THERAPY, 2017, 8 (02) : 275 - 291
[27] Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
Marc Evans
Barrie Chubb
Jens Gundgaard
[J]. Diabetes Therapy, 2017, 8 : 275 - 291
[28] Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK
McEwan, Phil
Poole, Chris D.
Tetlow, Tony
Holmes, Paul
Currie, Craig J.
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 : S21 - S31
[29] Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA
Barnaby Hunt
Michelle Mocarski
William J. Valentine
Jakob Langer
[J]. Advances in Therapy, 2017, 34 : 1500 - 1501
[30] The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting
Drummond, Russell
Malkin, Samuel
Du Preez, Michelle
Lee, Xin Ying
Hunt, Barnaby
[J]. DIABETES OBESITY & METABOLISM, 2018, 20 (10): : 2371 - 2378

← 1 2 3 4 5 →